Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: A meta-analysis using individual patient data

Annals of Oncology

Volumn 24, Issue 12, 2013, Pages 3028-3034

  Raja, F A ^a   Counsell, N ^a   Colombo, N ^b   Pfisterer, J ^c   du Bois, A ^d   Parmar, M K ^e   Vergote, I B ^f   Gonzalez Martin, A ^g   Alberts, D S ^h   Plante, M ⁱ   Torri, V ^j   Ledermann, J A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c STÄDTISCHES KLINIKUM SOLINGEN   (Germany)

^d Horst Schmidt Klinik   (Germany)

^e MEDICAL RESEARCH COUNCIL   (United Kingdom)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g MD Andersen Cancer Centre   (Spain)

^h UNIVERSITY OF ARIZONA   (United States)

ⁱ UNIVERSITÉ LAVAL   (Canada)

^j MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

more..

Author keywords

IPD meta analysis; Recurrent ovarian cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIRUBICIN; PACLITAXEL; PLATINUM;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; HUMAN; META ANALYSIS; OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT DURATION;

IPD META-ANALYSIS; RECURRENT OVARIAN CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84888789158     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt406     Document Type: Article

References (20)

1. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer:A Gynecologic Oncology Group Study. J Clin Oncol 2003; 21: 3194-3200.
2. du Bois A, Luck HJ, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320-1329.
3. Blackledge G, Lawton F, Redman C et al. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 1989; 59: 650-653.
4. Gore ME, Fryatt I, Wiltshaw E et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990; 36: 207-211.
5. Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389-393.
6. Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099-2106.
7. Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006; 24: 4699-4707.
8. Gonzalez-Martin AJ, Calvo E, Bover I et al. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Ann Oncol 2005; 16: 749-755.
9. Alberts DS, Liu PY, Wilczynski SP et al. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol Oncol 2008; 108: 90-94.
10. Bolis G, Scarfone G, Giardina G et al. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. Gynecol Oncol 2001; 81: 3-9.
11. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994; 309: 1286-1291.
12. Borenstein MHL, Higgins JPT, Rothstein HR. Introduction to Meta-analysis. In John Wiley & Sons, UK: Chichester 2009.
13. Friedlander M, Hancock KC, Rischin D et al. A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010; 119: 32-37.
14. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010; 28: 3323-3329.
15. Aghajanian C, Blank SV, GoffBA et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30: 2039-2045.
16. Gelmon KA, Tischkowitz M, Mackay H et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011; 12: 852-861.
17. Audeh MW, Carmichael J, Penson RT et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376: 245-251.
18. Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in platinumsensitive relapsed ovarian cancer. N Engl J Med 2012; 366: 1382-1392.
19. Bruchim I, Jarchowsky-Dolberg O, Fishman A. Advanced (>second) line chemotherapy in the treatment of patients with recurrent epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 2012; 166: 94-98.
20. Hanker LC, Loibl S, Burchardi N et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol 2012; 23: 2605-2612.